View Exam | PowerPak

1. Which of the following mutations does not have an FDA-approved targeted therapy in NSCLC?

A. BRAF B. KRAS C. NTRK D. EGFR

2. When a patient with a driver mutation experiences progression on treatment, what is the gold standard of care?

A. Obtain a liquid biopsy only B. Conduct molecular testing on original biopsy sample preserved by the lab C. Repeat tissue biopsy to obtain a new tissue sample for molecular testing or consider a liquid biopsy in those patients where a tissue biopsy cannot be safely obtained D. Any of these will work

3. NGS testing reveals your NSCLC patient has a tumor positive for EGFR L858R substitution. Which of the following is the most appropriate regimen for her NSCLC?

A. Gefitinib 250 mg PO daily B. Entrectinib 600 mg PO daily C. Carboplatin/pemetrexed IV Q3weeks D. Osimertinib 80 mg PO daily

4. Which of the following is the most appropriate first-line therapy for ALK-rearranged metastatic NSCLC with CNS involvement?

A. Crizotinib 250 mg PO BID B. Entrectinib 600 mg PO once daily C. Alectinib 600 mg PO BID D. Osimertinib 80 mg PO once daily

Maintenance is scheduled for 05/16/2024 5:00 PM EST - 05/17/2024 5:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following mutations does not have an FDA-approved targeted therapy in NSCLC?

2. When a patient with a driver mutation experiences progression on treatment, what is the gold standard of care?

3. NGS testing reveals your NSCLC patient has a tumor positive for EGFR L858R substitution. Which of the following is the most appropriate regimen for her NSCLC?

4. Which of the following is the most appropriate first-line therapy for ALK-rearranged metastatic NSCLC with CNS involvement?

« Return to Activity

Maintenance is scheduled for 05/16/2024 5:00 PM EST - 05/17/2024 5:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following mutations does not have an FDA-approved targeted therapy in NSCLC?

2. When a patient with a driver mutation experiences progression on treatment, what is the gold standard of care?

3. NGS testing reveals your NSCLC patient has a tumor positive for EGFR L858R substitution. Which of the following is the most appropriate regimen for her NSCLC?

4. Which of the following is the most appropriate first-line therapy for ALK-rearranged metastatic NSCLC with CNS involvement?

« Return to Activity

Customers who Purchased
this Activity also Purchased